SCHEMBL6777933

SCHEMBL6777933

N=C(N)Nc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 13/20 0.64
ITGB1 P05556 10/20 0.64
ITGAV P06756 10/20 0.64
ITGA5 P08648 10/20 0.64
ITGB5 P18084 8/20 0.64
ITGB6 P18564 8/20 0.64
ITGB8 P26012 8/20 0.64
ITGA8 P53708 8/20 0.64
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GPR139 Q6DWJ6 1/20 0.48
SLC6A9 P48067 1/20 0.44
ITGA2B P08514 3/20 0.44
EPHX2 P34913 1/20 0.43
RHOC P08134 2/20 0.41
RHOA P61586 2/20 0.41
MDM4 O15151 2/20 0.41
MDM2 Q00987 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783032 0.95 ITGB3 (0.72) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL6778978 0.90 ITGB3 (0.55) ITGB3ITGB1ITGAVITGA5ITGB5
Trifluoroacetic Acid SCHEMBL3835291 0.88 ITGB3 (0.51) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL7838264 0.88 ITGB3 (0.51) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL242674 0.88 ITGB3 (0.55) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL7341807 0.86 ITGB3 (0.63) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL244261 0.86 ITGB3 (0.50) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL6779336 0.86 ITGB3 (0.49) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL6776866 0.86 ITGB3 (0.53) ITGB3ITGB1ITGAVITGA5ITGB5
SCHEMBL6773834 0.86 ITGB3 (0.51) ITGB3ITGB1ITGAVITGA5ITGB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP claimed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed